Global Cardiovascular Drugs Market 2009-2024

Publication Date	June 2009
Publisher	Visiongain
Product Type	Report
Pages	132
ISBN Number	not applicable
Product Code	VIS00131

Buy this product or for assistance call +44 20 7060 7474

PDF £1,499.00$2493 | €1678

FAX Order above formats by FAX

Summary

Expanding Patent Populations and Disease Prevalence - Our New Pharma Report Highlights Sales Opportunities

Cardiovascular disorders are leading causes of death worldwide. Cardiovascular therapeutics form a central part of the global pharmaceutical market, with a wide range of treatments, including leading blockbusters. As the patient population grows and cardiovascular diseases become more prevalent, cardiovascular drugs have the potential for continued sales growth in both mature and emerging markets. Our new pharma report - Global Cardiovascular Drugs Market 2009-2024 - explains how, showing you where the opportunities for growth will lie from 2009 onwards.

Predictions state that total revenues in the cardiovascular disorders market will increase steadily from 2009. This report reviews commercial prospects for therapeutics directly related to cardiovascular incidents, agents such as platelet aggregation inhibitors, anticoagulants and fibrinolytics in particular. We include preventive therapeutics - such as antihypertensives and statins - in the overall analysis, even although they are not the main focus of this report.

The years 2011 to 2015 will mark a period of high volatility in the cardiovascular market as key products - including blockbusters Plavix and Lovenox - face patent expiry. What types of therapeutic agent will enter the market from 2009 onwards, and what are their sales prospects? Where do the main opportunities lie, and what are the threats in this market? What are the principal market drivers and restraints? This report will provide you with the analytical information that you need to understand current trends and future prospects in this market area, covering those and other questions. In particular, we discuss commercial prospects for the following products in detail, including future sales values:

Platelet aggregation inhibitors
Anticoagulant drugs
Nitrates
Fibrinolytics.

Comprehensive analysis of the cardiovascular market area

Global Cardiovascular Drugs Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 60 tables and figures and three full interviews with experts. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy Global Cardiovascular Drugs Market 2009-2024

Through buying this report you will receive the following benefits:

You will receive a review of the existing market for cardiovascular disorder therapeutics
You will receive overall revenue forecasts from 2009 to 2024, at whole market and sub-market levels for the sector
You will find out where leading products and companies are heading, with detailed sales forecasts from 2009 to 2024
You will receive forecast revenues for leading geographical markets
You will receive expert opinions from original research interviews
You will receive well-informed analyses of market drivers and restraints, including SWOT analysis for the cardiovascular sector
You will receive important pipeline information, seeing how present R&D is shaping the future of the cardiovascular market.

Content

1 Executive Summary
- 1.1 Aims of This Report
- 1.2 Chapter Overview
2 Cardiovascular Disease: An Overview
- 2.1 Financial Cost
- 2.2 Types of Cardiovascular and Cerebrovascular Disease
  - 2.2.1 Ischaemic Heart Disease
  - 2.2.2 Stroke
  - 2.2.3 Acute Myocardial Infarction
  - 2.2.4 Other Disorders
- 2.3 Risk Factors
- 2.4 Prevalence
  - 2.4.1 Ischaemic Heart Disease Remains the World's Leading Cause of Death
  - 2.4.2 Hypertensive Heart Disease on the Rise
3 Therapeutic Categories
- 3.1 Platelet Aggregation Inhibitors
  - 3.1.1 Glycoprotein Inhibitors
  - 3.1.2 COX Inhibitors and Aspirin
  - 3.1.3 Thienopyridines
- 3.2 Anticoagulants
  - 3.2.1 Heparins
  - 3.2.2 Vitamin K Antagonists and Warfarin
  - 3.2.3 Combined Therapy
- 3.3 Nitrates
- 3.4 Thromobolytics and Fibrinolytics
  - 3.4.1 Streptokinase and Urokinase
  - 3.4.2 Tissue Plasminogen Activators (t-PA)
  - 3.4.3 Other Thrombolytic Agents
- 3.5 Cardiac Glycosides
- 3.6 Anti-Arrhythmic Agents
- 3.7 Prevention of Disease
  - 3.7.1 Antihypertensives
  - 3.7.2 Lipid-Lowering Treatments
4 Global Market 2009-2024
- 4.1 Key Findings
- 4.2 Leading Companies
- 4.3 Forecast for the Overall Cardiovascular Market, 2009-2024
- 4.4 The Market for Acute Cardiovascular Therapeutics, 2009-2024
- 4.5 The Future of Blockbusters in the Market
- 4.6 Overview of the Market
5 Platelet Aggregation Inhibitors, 2009-2024
- 5.1 Key Findings
- 5.2 Platelet Aggregation Inhibitors Market, 2009-2024
- 5.3 High Revenues
- 5.4 Top Product Plavix
  - 5.4.1 Generic Competition Set to Strike
  - 5.4.2 Branded Competition: Marketed and in the Pipeline
- 5.5 Otsuka Pharmaceutical's Pletal
  - 5.5.1 Pletal Facing Several Abbreviated New Drug Applications
- 5.6 Boehringer Ingelheim's Asanantin
  - 5.6.1 Aiming for Higher Revenues
- 5.7 Aspirin Cardio
  - 5.7.1 OTC Treatments for the Prevention of Cardiovascular Disease?
- 5.8 The Future of Platelet Aggregation Inhibitors
6 Anticoagulants, 2009-2024
- 6.1 Key Findings
- 6.2 Total Anticoagulant Market, 2009-2024
- 6.3 Heparins Market, 2009-2024
- 6.4 Lovenox Leads the Market
  - 6.4.1 Competition for Lovenox
- 6.5 Fragmin
  - 6.5.1 Life Cycle Management and Competition
- 6.6 Fraxiparine
- 6.7 Market Share for Heparins, 2009, 2014, 2019 and 2024
- 6.8 Vitamin K Antagonists Market, 2009-2024
  - 6.8.1 Leading Product Coumadin
  - 6.8.2 Generic Competition for Warfarin
7 Nitrates, 2009-2024
- 7.1 Key Findings
- 7.2 Nitrates Market, 2009-2024
- 7.3 The Future of Nitrates
8 Fibrinolytics, 2009-2024
- 8.1 Key Findings
- 8.2 Fibrinolytics, 2009-2024
- 8.3 Activase: Leading the Category
  - 8.3.1 Competition and the Treatment Window
- 8.4 Second-Generation Drug Metalyse: Aiming for the Top?
  - 8.4.1 Mode of Administration May Give Metalyse the Edge
  - 8.4.2 ASSENT and TROICA Studies: A Mixed Message
9 Other Product Categories, 2009-2024
- 9.1 Cerebral and Peripheral Therapeutics
  - 9.1.1 New Products in the Pipeline
- 9.2 The Future of Anti-Arrhythmic Agents
  - 9.2.1 Thin Pipeline and Safety Scares
- 9.3 Cardiac Glycosides: Low Revenues
  - 9.3.1 Digitalis: Alleviating Symptoms or Ineffective Therapy?
10 Preventive Therapeutics, 2009-2024
- 10.1 Key Findings
- 10.2 Antihypertensives
  - 10.2.1 Forecast for the Overall Antihypertensive Market, 2009-2024
  - 10.2.2 Angiotensin II Antagonists Lead the Market
  - 10.2.3 Generic Threat
  - 10.2.4 Overall Assessment of the Market
- 10.3 Lipid-Lowering Therapeutics, 2009-2024
  - 10.3.1 Forecast for the Overall Lipid Lowering Market, 2009-2024
  - 10.3.2 Statins: A Success Story So Far
- 10.4 High Revenues
11 Geographical Breakdown of the Market
- 11.1 USA
- 11.2 Europe
- 11.3 Emerging Markets
  - 11.3.1 China
  - 11.3.2 India
12 SWOT Analysis of the Market
- 12.1 Principal Drivers
  - 12.1.1 Increasing Prevalence of Disease Drives the Market
  - 12.1.2 High Economic Cost of Disease
  - 12.1.3 Risk Factors: Management Rather than Cure
  - 12.1.4 Switching to OTC
  - 12.1.5 Novel Therapeutics Poised to Meet Needs in the Patient Population
- 12.2 Principal Restraints
  - 12.2.1 The Threat of Generic Products
  - 12.2.2 Downward Cost Pressures
  - 12.2.3 Buyer's Market?
  - 12.2.4 Maturation of the Overall Market May Limit Growth
  - 12.2.5 Antihypertensives: Is the Market Maturing?
  - 12.2.6 Challenges to the Statins Industry
- 12.3 Concluding Remarks on the Future of the Market
13 Expert Opinions
- 13.1 Professor Jeremy Pearson
  - 13.1.1 The Future of Stem Cells in the Treatment of Cardiovascular Disorders
  - 13.1.2 Time Frame for Research and Development
  - 13.1.3 Current Challenges for This Type of Therapeutics
- 13.2 Dr Mariola S??hngen
  - 13.2.1 Unmet Needs for Patients Suffering from Ischaemic Strokes
  - 13.2.2 Trends in Research and Development
  - 13.2.3 Limitations of Anti-Clotting Drugs: New Developments
- 13.3 Dr Josh Reece
  - 13.3.1 The Future of Stem Cells in the Treatment of Cardiovascular Disorders
  - 13.3.2 Stem Cells: Niche or Mainstream?
  - 13.3.3 Osiris Therapeutics' Prochymal
14 Pipelines and Future Trends
- 14.1 Gene Therapy: A Growing Area of Research
  - 14.1.1 Potential Therapeutic Areas
  - 14.1.2 Public Acceptance of Gene Therapy
- 14.2 Stem Cells: High Potential?
  - 14.2.1 Osiris Therapeutics
  - 14.2.2 ReNeuron
- 14.3 Treatment Windows and New Opportunities
- 14.4 Novel Antithrombotic Drugs: Limitations in the Existing Market
  - 14.4.1 Servier's Terutroban
  - 14.4.2 AstraZeneca's Brilinta
  - 14.4.3 Schering-Plough's Protara
  - 14.4.4 Schering-Plough's SCH 530348
- 14.5 Long-Term Oral Anticoagulants
15 Conclusions
- 15.1 High Revenues
- 15.2 Impending Patent Expiries
- 15.3 Expanding Market
- 15.4 Rehabilitation on the Rise
- 15.5 Summary
List of Tables
- Table 2.1 Leading Causes of Death World Wide, 2004 and 2030
- Table 3.1 Antihypertensive Drugs, Their Effects and Side Effects
- Table 3.2 Factors Influencing Plasma Lipid Levels
- Table 4.1 Leading Companies in the Cardiovascular Therapeutic Market, World Sales ($m) and Market Share (%), 2008
- Table 4.2 Cardiovascular Market, World Sales ($m), 2009-2024
- Table 4.3 Acute Therapeutics by Category, World Sales ($m) and Market Share (%), 2009 and 2014
- Table 4.4 Key Products in the Cardiovascular Market, World Sales ($m) and Market Share (%), 2008
- Table 5.1 Platelet Aggregation Inhibitors, World Sales ($m), 2008-2014
- Table 5.2 Platelet Aggregation Inhibitors, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 6.1 Anticoagulants, World Sales ($m), 2008-2014
- Table 6.2 Anticoagulants, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 6.3 Heparins, World Sales ($m), 2008-2014
- Table 6.4 Heparins, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 6.5 Vitamin K Antagonists, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 7.1 Nitrates, World Sales ($m), 2008-2014
- Table 7.2 Nitrates, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 8.1 Fibrinolytics, World Sales ($m), 2008-2014
- Table 8.2 Fibrinolytics, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 9.1 Other Product Categories, World Sales ($m), 2008-2014
- Table 9.2 Other Product Categories, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 10.1 Antihypertensive Market, World Sales ($m), 2008-2014
- Table 10.2 Lipid-Lowering Therapeutics, World Sales ($m), 2008-2014
- Table 10.3 Lipid-Lowering Therapeutics, World Sales ($m), 2009, 2014, 2019 and 2024
- Table 11.1 Geographical Breakdown of the World Market, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
- Table 12.1 SWOT Analysis for the Cardiovascular Market, 2009
List of Figures
- Figure 4.1 Leading Companies in the Cardiovascular Therapeutic Market, Market Share (%), 2008
- Figure 4.2 Preventive vs. Acute Therapeutics, Market Share (%), 2009, 2014, 2019 and 2024
- Figure 4.3 Sales ($m) for the Global Cardiovascular Market, 2008-2024
- Figure 4.4 Acute Therapeutics by Category, Market Share (%), 2008
- Figure 4.5 Sales ($m) for the Global Acute Cardiovascular Therapy Market, 2008-2024
- Figure 5.1 Market Share (%) for the Leading Products in the Platelet Aggregation Inhibitor Market, 2008
- Figure 5.2 Plavix, World Sales ($m), 2008-2024
- Figure 5.3 Pletal, World Sales ($m), 2008-2024
- Figure 5.4 Asanantin, World Sales ($m), 2009-2024
- Figure 5.5 Aspirin Bayer, World Sales ($m), 2008-2024
- Figure 5.6 Platelet Aggregation Inhibitors, Key Products Market Share (%), 2009, 2014, 2019 and 2024
- Figure 6.1 Anticoagulants, World Sales ($m), 2008-2024
- Figure 6.2 Heparins, World Sales ($m), 2008-2024
- Figure 6.3 Anticoagulants, Market Share (%), 2008
- Figure 6.4 Lovenox, World Sales ($m), 2008-2024
- Figure 6.5 Fragmin and Fraxiparine, World Sales ($m), 2008-2024
- Figure 6.6 Heparins, Market Share (%), 2009, 2014, 2019 and 2024
- Figure 6.7 Vitamin K Antagonists, World Sales ($m), 2009-2024
- Figure 6.8 Vitamin K Antagonists, Market Share (%), 2008
- Figure 6.9 Vitamin K Inhibitors, Market Share (%), 2009, 2014, 2019 and 2024
- Figure 7.1 Nitrates, World Sales ($m), 2008-2024
- Figure 8.1 Activase, World Sales ($m), 2008-2024
- Figure 8.2 Metalyse, World Sales ($m), 2008-2024
- Figure 8.3 Key Fibrinolytics, Market Share (%), 2009, 2014, 2019 and 2024
- Figure 9.1 Other Product Categories, World Sales ($m), 2009, 2014, 2019 and 2024
- Figure 10.1 Antihypertensives, World Sales ($m), 2008-2024
- Figure 10.2 Market Share (%) for the Various Types of Antihypertensives, 2008
- Figure 10.3 World Sales ($m) for Statins and Non-Statin Lipid-Lowering Therapeutics, 2008-2024
- Figure 10.4 Market Share (%) for Cholesterol Lowering Therapeutics, 2008
- Figure 10.5 Types of Statins, World Sales ($m), 2008
- Figure 10.6 Preventive and Acute Therapeutics, Market Share (%), 2008
- Figure 11.1 Geographical Breakdown of the World Market, Market Share (%), 2008
- Figure 11.2 Market Share (%) for Key Countries, 2009, 2014, 2019 and 2024
- Figure 11.3 Market Share (%) for the European Market, 2009, 2014, 2019 and 2024
- Figure 11.4 Geographical Areas Market Share (%), 2009, 2014, 2019 and 2024
Companies Listed
- Abbott
- Acino
- Almirall
- Alpharma
- Amphastar Pharmaceuticals
- AnGes MG
- Apotex
- AstraZeneca
- Barr
- Bayer Schering Pharma
- Biovail Pharmaceuticals
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Centocor
- Chiesi Pharmaceuticals
- Choong-Wae Pharmaceuticals
- Chorepharma
- Daiichi Sankyo
- Dainippon Sumitomo
- Dong-A
- Eli Lilly
- Eon Labs
- Esteve
- Genentech
- Genzyme
- GlaxoSmithKline
- Ipsen
- Johnson & Johnson
- Kyowa Hakko
- LIBBS
- Meda
- Menarini
- Merck & Co
- Mitsubishi Kasei
- Mitsubishi Tanabe
- Momenta Pharmaceuticals
- Mylan
- Novartis
- Nycomed
- Otsuka
- Paion
- Pfizer
- Portola
- Ranbaxy
- Ratiopharm
- ReNeuron
- Roche
- Sandoz
- Sanofi-Aventis
- Servier
- Sigma-Tau
- Shionogi
- Solvay
- Taro (Israel)
- Teva Pharmaceutical Industries
- Watson